Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Atreca stock price, quote, forecast and news

BCEL
US04965G1094
A2PLNM

Price

0.09
Today +/-
+0
Today %
+0 %
P

Atreca stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Atreca stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Atreca stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Atreca stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Atreca's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Atreca Stock Price History

DateAtreca Price
6/14/20240.09 undefined
6/13/20240.09 undefined

Atreca Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Atreca, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Atreca from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Atreca’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Atreca. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Atreca’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Atreca’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Atreca’s growth potential.

Atreca Revenue, EBIT and net profit per share

DateAtreca RevenueAtreca EBITAtreca Net Income
2029e0 undefined0 undefined0 undefined
2028e0 undefined-70.38 M undefined-51.36 M undefined
2027e0 undefined-59.16 M undefined-43.68 M undefined
2026e0 undefined-59.05 M undefined-41.25 M undefined
2025e0 undefined-49.98 M undefined-30.33 M undefined
2024e0 undefined-40.29 M undefined-26.29 M undefined
2023e0 undefined-83.49 M undefined-82.5 M undefined
20220 undefined-98.29 M undefined-97.16 M undefined
20210 undefined-110.3 M undefined-109.33 M undefined
20200 undefined-88.88 M undefined-86.34 M undefined
20190 undefined-72.57 M undefined-67.48 M undefined
20180 undefined-39.57 M undefined-37.94 M undefined
20170 undefined-29.44 M undefined-27.53 M undefined

Atreca Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2017201820192020202120222023e2024e2025e2026e2027e2028e2029e
0000000000000
-------------
-------------
0000000000000
-29-39-72-88-110-98-83-40-49-59-59-700
-------------
-27-37-67-86-109-97-82-26-30-41-43-510
-37.0481.0828.3626.74-11.01-15.46-68.2915.3836.674.8818.60-
26.7826.7827.9731.9237.0438.590000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Atreca Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Atreca is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201720182019202020212022
           
30.6114.5172.6240.111770.5
000000
000000
000000
1.32.43.18.153.4
31.9116.9175.7248.212273.9
3.84.15.819.84374
0010.80310
000000
000000
000000
0.30.333.13.63
4.14.419.622.977.677
36121.3195.3271.1199.6150.9
           
89.4209.70000
2.13.6351492.4514.8535.6
-58.7-96.6-164.1-250.4-359.8-456.9
000100-100-300
000000
32.8116.7186.9242.1154.978.4
0.61.32.15.23.41.7
2.135.410.311.613.2
00.20.41.821.3
000000
1000010000
2.84.57.917.41716.2
100100100000
000000
0.40.40.812.628.260.3
0.50.50.912.628.260.3
3.358.83045.276.5
36.1121.7195.7272.1200.1154.9
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Atreca provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Atreca's financial health and stability.

Assets

Atreca's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Atreca must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Atreca after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Atreca's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201720182019202020212022
-27-37-67-86-109-97
111245
000000
001425-8
015121819
000000
000000
-25-34-58-66-60-80
-1-1-3-5-350
-820-27-1598912
-722-24-15312413
000000
000000
3412013412953
3412013112853
---2.00---
000000
010644-9633-64
-26.48-36.46-61.99-71.7-96.01-81.61
000000

Atreca stock margins

The Atreca margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Atreca. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Atreca.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Atreca's sales revenue. A higher gross margin percentage indicates that the Atreca retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Atreca's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Atreca's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Atreca's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Atreca. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Atreca's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Atreca Margin History

Atreca Gross marginAtreca Profit marginAtreca EBIT marginAtreca Profit margin
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Atreca Stock Sales Revenue, EBIT, Earnings per Share

The Atreca earnings per share therefore indicates how much revenue Atreca has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Atreca earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Atreca's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Atreca’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Atreca's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Atreca Revenue, EBIT and net profit per share

DateAtreca Sales per ShareAtreca EBIT per shareAtreca Earnings per Share
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined-1.3 undefined
2027e0 undefined0 undefined-1.1 undefined
2026e0 undefined0 undefined-1.04 undefined
2025e0 undefined0 undefined-0.77 undefined
2024e0 undefined0 undefined-0.66 undefined
2023e0 undefined0 undefined-2.08 undefined
20220 undefined-2.55 undefined-2.52 undefined
20210 undefined-2.98 undefined-2.95 undefined
20200 undefined-2.78 undefined-2.7 undefined
20190 undefined-2.59 undefined-2.41 undefined
20180 undefined-1.48 undefined-1.42 undefined
20170 undefined-1.1 undefined-1.03 undefined

Atreca business model

Atreca Inc is a biotechnology company that specializes in researching and developing novel immunotherapies for various diseases. It was founded in 2010 by a team of renowned scientists who share a common passion for discovering innovative approaches to treating serious illnesses. The company's business model is based on the identification of antigens - biological molecules that the immune system recognizes and responds to - from the cells of patients suffering from severe diseases such as cancer or autoimmune disorders. Atreca utilizes its proprietary technology platform, called Immune Repertoire Capture (IRC) technology, to isolate and identify these antigens. Once identified, the company can use these antigens to develop new immunotherapies that activate the patient's immune system to fight the disease. These personalized immunotherapies have the potential to be more specific and effective than conventional approaches used on a broad basis. Atreca has split into two main areas to optimize its business model: monetizing research and development and making its technology platform accessible to other companies. The company's research and development department focuses on the discovery and development of personalized immunotherapies for various types of cancer and autoimmune disorders. The company recently entered into a significant milestone agreement with a subsidiary of Merck to develop personalized immunotherapies for selected types of cancer. Atreca also has a separate business unit that provides its IRC technology to other companies. This business unit offers contract research and consulting services to assist other biotechnology and pharmaceutical clients in the identification of antigens and the development of personalized immunotherapies. By providing IRC technology to other companies, Atreca has tapped into a new revenue stream that allows it to offer unique and effective biotechnology solutions in the future. In terms of its products, Atreca has several potential immunotherapy candidates in its pipeline, some of which are already being tested in clinical trials. One of its key products is a personalized immunotherapy drug called ATRC-101, which targets the treatment of patients with metastatic solid tumors. The drug utilizes Atreca's IRC technology to identify the antigens in the patients and develop personalized immunotherapies based on these antigens. Furthermore, the company has additional drug candidates in the development phase and is also considering the possibility of venturing into other disease areas such as infectious diseases. Atreca has the potential to become a key player in the biotechnology industry by providing personalized and effective immunotherapies for a variety of diseases. Atreca is one of the most popular companies on Eulerpool.com.

Atreca SWOT Analysis

Strengths

1. Strong technological capabilities, allowing for innovative product development.

2. Highly skilled and experienced management team.

3. Robust intellectual property portfolio, providing a competitive advantage.

4. Solid financial position with significant funding for research and development.

Weaknesses

1. Relatively new in the market, lacking brand recognition compared to established competitors.

2. Limited product portfolio with a dependency on a few key products.

3. High operating costs due to ongoing research and clinical trials.

4. Vulnerability to regulatory changes impacting the healthcare industry.

Opportunities

1. Growing demand for personalized medicine offers opportunities for tailored therapeutics.

2. Increasing investment in biotechnology and healthcare sectors providing potential partnerships and collaborations.

3. Expanding global market for oncology therapeutics, which is a key focus area for Atreca Inc.

4. Emerging trends in immuno-oncology creating opportunities for innovative treatment approaches.

Threats

1. Intense competition from established biopharmaceutical companies.

2. Uncertainty regarding regulatory approval for new products.

3. Economic downturns impacting healthcare expenditure and market demand.

4. Potential risks associated with clinical trial outcomes and product efficacy.

Atreca Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Atreca historical P/E ratio, EBIT, and P/S ratio.

Atreca shares outstanding

The number of shares was Atreca in 2023 — This indicates how many shares 38.59 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Atreca earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Atreca's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Atreca’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Atreca's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Atreca.

Atreca latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-0.39 -0.39  (0.51 %)2023 Q3
6/30/2023-0.58 -0.49  (15.33 %)2023 Q2
3/31/2023-0.57 -0.54  (5.41 %)2023 Q1
12/31/2022-0.6 -0.53  (12.21 %)2022 Q4
9/30/2022-0.74 -0.6  (18.93 %)2022 Q3
6/30/2022-0.72 -0.72  (0.19 %)2022 Q2
3/31/2022-0.8 -0.65  (18.8 %)2022 Q1
12/31/2021-0.77 -0.79  (-2.58 %)2021 Q4
9/30/2021-0.75 -0.74  (1.8 %)2021 Q3
6/30/2021-0.71 -0.72  (-1.65 %)2021 Q2
1
2

Eulerpool ESG Scorecard© for the Atreca stock

Eulerpool World ESG Rating (EESG©)

41/ 100

🌱 Environment

45

👫 Social

39

🏛️ Governance

39

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Atreca list of shareholders

%
Name
Stocks
Change
Date
5.55443 % Boxer Capital, L.L.C.2,202,333012/31/2023
5.49180 % Baker Bros. Advisors LP2,177,49902/22/2024
2.30175 % Bill & Melinda Gates Foundation912,642012/31/2023
2.29332 % The Vanguard Group, Inc.909,300-419,62312/31/2023
1.54352 % BlackRock Institutional Trust Company, N.A.612,007-295,98512/31/2023
1.11640 % Redmile Group, LLC442,653012/31/2023
0.97769 % Aisling Capital Management LP387,653012/31/2023
0.93051 % Robinson (William Hewitt)368,94802/22/2024
0.89792 % Renaissance Technologies LLC356,02414,10012/31/2023
0.81339 % Serafini (Tito A)322,511-20,7884/1/2024
1
2
3
4
5
...
10

Atreca Executives and Management Board

Mr. John Orwin58
Atreca President, Chief Executive Officer, Principal Financial Officer, Director (since 2018)
Compensation 927,033
Dr. Tito Serafini59
Atreca Co-Founder, Director (since 2024)
Compensation 665,504
Dr. William Robinson55
Atreca Director
Compensation 312,774
Mr. Brian Atwood70
Atreca Independent Chairman of the Board
Compensation 97,774
Mr. Franklin Berger73
Atreca Independent Director
Compensation 71,774
1
2
3

Most common questions regarding Atreca

What values and corporate philosophy does Atreca represent?

Atreca Inc represents values of collaboration, innovation, and patient-centricity. The company is dedicated to creating transformative therapeutics through its proprietary drug discovery platform. By harnessing the power of the immune system, Atreca aims to develop novel treatments for a range of diseases, including cancer and autoimmune disorders. Atreca's corporate philosophy revolves around partnering with leading academic institutions and biopharmaceutical companies to accelerate the development of breakthrough therapies. With a strong focus on scientific excellence and strategic collaborations, Atreca Inc strives to make a positive and lasting impact on patient lives.

In which countries and regions is Atreca primarily present?

Atreca Inc is primarily present in the United States.

What significant milestones has the company Atreca achieved?

Atreca Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in June 2019, raising approximately $125 million. In 2020, Atreca initiated a Phase 1b clinical trial for its lead product candidate, ATRC-101, in patients with select solid tumor types. Additionally, Atreca expanded its collaborations with global pharmaceutical companies, such as BeiGene, to further advance its discovery platform and accelerate the development of novel therapeutics. The company has consistently demonstrated its commitment to innovation and growth in the field of cancer therapeutics.

What is the history and background of the company Atreca?

Atreca Inc is a biotechnology company founded in 2010. Headquartered in California, the company specializes in developing novel immune-based therapeutics for the treatment of various diseases. Atreca's innovative approach combines proprietary technologies with advanced data science to discover and develop potential drug candidates. The company focuses on identifying targets and generating therapeutic antibodies aimed at addressing unmet medical needs. With a team of experienced scientists and strategic collaborations, Atreca Inc strives to make significant contributions to the field of immunotherapy. By leveraging its expertise and cutting-edge technologies, the company aims to improve patient outcomes and advance the understanding of the immune system.

Who are the main competitors of Atreca in the market?

The main competitors of Atreca Inc in the market include companies such as Agenus Inc, Bristol-Myers Squibb, and Merck & Co. These companies operate in the same biopharmaceutical industry as Atreca Inc, focusing on the development and commercialization of innovative therapies. While Atreca Inc stands out with its unique approach to immunotherapy and drug discovery, it competes against these industry giants to capture market share and draw investors' attention. By diligently conducting research and staying at the forefront of medical advancements, Atreca Inc strives to distinguish itself in this highly competitive landscape.

In which industries is Atreca primarily active?

Atreca Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Atreca?

Atreca Inc. specializes in the discovery and development of innovative antibody-based therapeutics. The company's business model revolves around leveraging its proprietary drug discovery platform to identify and develop novel monoclonal antibodies with the potential to address a wide range of diseases. By focusing on the human immune response, Atreca aims to uncover and select therapeutically-relevant antibodies that target specific antigens. Through collaborations and partnerships, Atreca further accelerates the development and commercialization of its candidates. With a strong emphasis on precision medicine, Atreca Inc. strives to revolutionize the treatment landscape by harnessing the power of the immune system to combat various illnesses.

What is the P/E ratio of Atreca 2024?

The Atreca P/E ratio is -0.13.

What is the P/S ratio of Atreca 2024?

The Atreca P/S ratio is 0.

What is the AlleAktien quality score of Atreca?

The AlleAktien quality score for Atreca is 2/10.

What is the revenue of Atreca 2024?

The revenue cannot currently be calculated for Atreca.

How high is the profit of Atreca 2024?

The expected Atreca profit is -26.29 M USD.

What is the business model of Atreca

Atreca Inc is a biopharmaceutical company specializing in the development of immunotherapies for cancer and autoimmune diseases. The company uses proprietary technologies and innovative approaches to identify and develop antibodies and other biomolecules that can specifically target and combat disease targets. Atreca's business model is based on the development of therapeutics using its own technology platforms. The company takes a three-pronged approach to utilize its technology platforms, which includes the identification of antibodies, the development of diagnostics, and the combination of therapeutic agents. One of Atreca's key products is its Immune Repertoire Capture (IRC) technology platform, which allows for the identification of antibodies against specific disease targets. IRC utilizes next-generation sequencing technology and bioinformatics to sequence and identify antibodies in the blood samples of patients and healthy donors. Based on this approach, Atreca has built an extensive library of antibodies that can be used for the development of therapeutics and diagnostics. Another important product of Atreca is its platform for the combination of therapeutic agents, which allows for the linking of multiple agents into a single molecule. This technology offers potentially synergistic effects to enhance the efficacy of therapeutics. This platform is currently being used in the clinical phase for cancer. Atreca also pursues a diagnostic strategy, which allows for the identification of disease-specific antibodies and their use as biomarkers for diagnostics and prognostics. This approach utilizes the IRC platform to identify unique antibody profiles for different disease states. The company has already entered partnerships with pharmaceutical companies to utilize their IRC technology for antibody identification and validation. To increase the value of its business model, Atreca has entered into partnerships with other biopharmaceutical companies to utilize its technology platforms for antibody production and the development of cancer therapies. The company also collaborates with several academic institutions to advance scientific progress in immunotherapy. In general, Atreca is a leading company in the field of immunotherapy with a unique technology platform that allows it to work faster and more efficiently than its competitors. Atreca focuses on utilizing its technology platforms to develop new and innovative therapeutics and diagnostics for the treatment of cancer and autoimmune diseases.

What is the Atreca dividend?

Atreca pays a dividend of 0 USD distributed over payouts per year.

How often does Atreca pay dividends?

The dividend cannot currently be calculated for Atreca or the company does not pay out a dividend.

What is the Atreca ISIN?

The ISIN of Atreca is US04965G1094.

What is the Atreca WKN?

The WKN of Atreca is A2PLNM.

What is the Atreca ticker?

The ticker of Atreca is BCEL.

How much dividend does Atreca pay?

Over the past 12 months, Atreca paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Atreca is expected to pay a dividend of 0 USD.

What is the dividend yield of Atreca?

The current dividend yield of Atreca is .

When does Atreca pay dividends?

Atreca pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Atreca?

Atreca paid dividends every year for the past 0 years.

What is the dividend of Atreca?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Atreca located?

Atreca is assigned to the 'Health' sector.

Wann musste ich die Aktien von Atreca kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Atreca from 9/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.

When did Atreca pay the last dividend?

The last dividend was paid out on 9/18/2024.

What was the dividend of Atreca in the year 2023?

In the year 2023, Atreca distributed 0 USD as dividends.

In which currency does Atreca pay out the dividend?

The dividends of Atreca are distributed in USD.

All fundamentals about Atreca

Our stock analysis for Atreca Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Atreca Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.